KYS05040 | 742104-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: KYS05040
• 英文别名: 4-[N-(4-aminobenzyl)acetamido]-2-(1-piperidinyl)-3-phenyl-3,4-dihydroquinazoline；N-(4-aminobenzyl)-2-(3-phenyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)acetamide；N-[(4-aminophenyl)methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
• CAS: 742104-68-3
• 化学式: C₂₈H₃₁N₅O
• 分子量: 453.587
• InChiKey: NEMYASVJMUEWED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  74
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氟苯磺酰氯 、 KYS05040 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以73%的产率得到KYS05042
  参考文献：
  名称：

  3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same

  摘要：

  本发明涉及3,4-二氢喹唑啉衍生物作为T型钙通道阻滞剂以及其制备方法。本发明还涉及包含该衍生物的组合物。本发明的3,4-二氢喹唑啉衍生物组合物可有效用于通过阻塞T型钙通道预防和治疗心绞痛、高血压、心肌病、疼痛和癫痫。

  公开号：

  US20050197351A1
• 作为产物：
  描述：

  2-nitrocinnamic acid 在 palladium on activated charcoal lithium hydroxide 、 硫酸 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 tin(ll) chloride 、 二溴三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 苯 为溶剂， 反应 22.0h， 生成 KYS05040
  参考文献：
  名称：

  Synthesis and SAR studies of a novel series of T-type calcium channel blockers

  摘要：

  For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among them, 9c (KYS05064, IC50 = 0.96 +/- 0.22 mu M) was found to be as potent as Mibefradil and also showed the highest selectivity for T-type Ca2+ channel with no effect on N-type Ca2+ channel. (c) 2006 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2006.01.005

文献信息

• Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers
  作者：Jae Yeol Lee、Seong Jun Park、Sung Jun Park、Min Joo Lee、Hyewhon Rhim、Seon Hee Seo、Ki-Sun Kim

  DOI：10.1016/j.bmcl.2006.07.046

  日期：2006.10

  This paper describes the preliminary biological results that novel T-type calcium channel blockers inhibit the growth of human cancer cells by blocking calcium influx into the cell, based on unknown mechanism on the cell cycle responsible for cellular proliferation. Among the selected compounds from compound library, compound 9c (KYS05041) was identified to be nearly equipotent with Cisplatin against some human cancers in the micromolar range. (c) 2006 Elsevier Ltd. All rights reserved.
• 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
  申请人：Korea Institute of Science and Technology

  公开号：EP1568695B1

  公开（公告）日：2016-03-09
• 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers
  作者：Yong Sup Lee、Bum Hoon Lee、Seong Jun Park、Soon Bang Kang、Hyewhon Rhim、Jin-Yong Park、Jung-Ha Lee、Seong-Woo Jeong、Jae Yeol Lee

  DOI：10.1016/j.bmcl.2004.04.090

  日期：2004.7

  For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS05001, IC50 = 0-9 muM) was nearly equipotent with mibefradil (IC50 = 0.84 muM) and inhibited LVA T-type Ca2+ channel with greater efficacy than HVA Ca2+ channel. (C) 2004 Elsevier Ltd. All rights reserved.
• US7271260B2
  申请人：——

  公开号：US7271260B2

  公开（公告）日：2007-09-18
• Synthesis and SAR studies of a novel series of T-type calcium channel blockers
  作者：Seong Jun Park、Sung Jun Park、Min Joo Lee、Hyewhon Rhim、Yoonjee Kim、Jung-Ha Lee、Bong Young Chung、Jae Yeol Lee

  DOI：10.1016/j.bmc.2006.01.005

  日期：2006.5

  For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among them, 9c (KYS05064, IC50 = 0.96 +/- 0.22 mu M) was found to be as potent as Mibefradil and also showed the highest selectivity for T-type Ca2+ channel with no effect on N-type Ca2+ channel. (c) 2006 Published by Elsevier Ltd.